CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases (CARBON): study protocol for a phase IB/IIA randomised controlled trialRob Coleman, Sarah Brown, Carlo Palmieri et al.|Trials|2020Cited by 15
A phase IB and randomised phase IIA trial of CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases: CARBON trial resultsMatthew Winter, Janet E. Brown, Rob Coleman et al.|Journal of bone oncology|2022Cited by 10
Abstract GS3-10: Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC)R. Charles Coombes, Stuart McIntosh, Sacha J. Howell et al.|Cancer Research|2022Cited by 7
Abstract P1-18-10: A clinical study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in patients with advanced triple negative breast cancer (TNBC)Sacha J. Howell, R. Charles Coombes, Laura Kenny et al.|Cancer Research|2022Cited by 5